LB Bohle – 10.06.2025
Nipro Vialex – 26th January 2025
PCI – 7th June 2024
Temax_Krautz

Current Edition

Nasal & Pulmonary Drug Development
Novo Nordisk 20 March 2024, 11:21
Carterra – 24th March 2025
Stoelzle – 15th May 2025

Annex 1-Implementation of the Final Draft

Annex 1 “Manufacture of Sterile Medicinal Products” was first published in 1971 and forms part of EudraLex Volume 4 [1], which interprets the basic principles of GMP as detailed in European Directive 2003/94/ EEC [2]. Annex 1 provides guidance on the minimum controls that are required to protect sterile medicinal products during manufacturing. Patrick Nieuwenhuizen, Director Senior Consultant at PharmaLex gives a brief overview of the new Annex 1. The overall message for manufacturers of sterile products is to ensure the systems and processes are in place to demonstrate sustainable control of the entire process and associated facilities, therewith ensuring product safety and ultimate protection of the patient.

Scott Pharma – 25.03.2025
Bespak – 21.05.2025
FujiFilm Skyscraper: 26th November 2024
Woolcool 26 March 2024, 16:16
Biopharma group 6 March 2024, 09:40
EyeC 18 March 2024, 13:10
Nipro – 09.06.2025
L.B. Bohle – 08.04.2025
Drug Discovery 2025, ELRIG – 04.07.2025